ATS 2022: Approach to Lung Nodules in 2022

Shaheen Islam

Post COVID-19 Lung Complications

3rd Advanced Lung Disease: Novel Therapies and Controversies Conference

M. Padilla

Approaching Sarcoidosis Therapy From a 21st Century Perspective

CHEST 2022 Coverage

D. Culver

A Radiologist's Approach to Subsolid Pulmonary Nodules

CHEST 2022 Coverage

A. Guttentag

Advances and Updates in Sarcoidosis: Diagnosis and Treatment of Pulm…

UCLA Health

J. Belperio

Interstitial Lung Disease in Rheumatic Diseases

University of Colorado Department of Medicine

M. Griffith

Bronchoscopic Imaging for Interstitial Lung Disease

CHEST 2022 Coverage

G. Zhi Cheng

Management and Treatment Decisions in Progressive Pulmonary Fibrosis

CHEST 2022 Coverage

T. Kulkarni

Sarcoidosis: Diagnosis and Management

University of Colorado Department of Medicine

N. Held

Interstitial Lung Disease in RA: RA-ILD Subtypes, Mortality Risk, RA…

RheumNow

J. Sparks, J. Cush

Rituximab versus Cyclophosphamide for the Treatment of Connective Ti…

Toby Maher

Management of Pulmonary Fibrosis in Clinical Practice

National Jewish Health

J. Solomon

Progressive ILD on Rheumatic Diseases - The Rheumatologists' Perspec…

WASOG - World Association of Sarcoidosis and Other Granulomatous Disorders

A. Hoffmann-Vold

EADV 2024 Insights: Eosinophilic Fasciitis

EADV 2024 Insights

F. Rongioletti

Challenges in ILD: Prediction With or Without Big Data

WASOG - World Association of Sarcoidosis and Other Granulomatous Disorders

T. Fingerlin

Interstitial Lung Disease: Multidisciplinary Discussion

UCLA Health

S. Sam Weigt, E. R. Volkmann, F. Abtin, M. Fishbein

Current and Evolving Paradigm of Anti-Inflammatory Therapy in Pulmon…

Temple Lung Center

R. Gupta

Update on the New ANA Classification System

Keck School of Medicine of USC

E. Taylor-Albert

Medical Marijuana in Rheumatology: Fact or Fiction?

Keck School of Medicine of USC

A. Wells

Identifying the Signs and Symptoms of Progressive Pulmonary Fibrosis

The France Foundation

V. Khangoora